These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
270 related items for PubMed ID: 14529915
21. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, Tueros L, Hanson L, Rosen A, Ruiz P, Miller J. Transplantation; 2008 Jul 15; 86(1):67-74. PubMed ID: 18622280 [Abstract] [Full Text] [Related]
22. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. Tran HTB, Acharya MK, McKay DB, Sayegh MH, Carpenter CB, Auchincloss H, Kirkman RL, Milford EL. J Am Soc Nephrol; 2000 Oct 15; 11(10):1903-1909. PubMed ID: 11004222 [Abstract] [Full Text] [Related]
23. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. Krämer BK, Klinger M, Vítko Š, Glyda M, Midtvedt K, Stefoni S, Citterio F, Pietruck F, Squifflet JP, Segoloni G, Krüger B, Sperschneider H, Banas B, Bäckman L, Weber M, Carmellini M, Perner F, Claesson K, Marcinkowski W, Ostrowski M, Senatorski G, Nordström J, Salmela K. Transplantation; 2012 Sep 15; 94(5):492-8. PubMed ID: 22858806 [Abstract] [Full Text] [Related]
24. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Hirose R, Roberts JP, Quan D, Osorio RW, Freise C, Ascher NL, Stock PG. Transplantation; 2000 Jan 27; 69(2):307-11. PubMed ID: 10670644 [Abstract] [Full Text] [Related]
25. Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients. Michielsen LA, van Zuilen AD, Verhaar MC, Wisse BW, Kamburova EG, Joosten I, Allebes WA, van der Meer A, Baas MC, Spierings E, Hack CE, van Reekum FE, Bots ML, Drop ACAD, Plaisier L, Seelen MAJ, Sanders JF, Hepkema BG, Lambeck AJ, Bungener LB, Roozendaal C, Tilanus MGJ, Voorter CE, Wieten L, van Duijnhoven EM, Gelens MACJ, Christiaans MHL, van Ittersum FJ, Nurmohamed SA, Lardy NM, Swelsen W, van der Pant KA, van der Weerd NC, Ten Berge IJM, Bemelman FJ, Hoitsma A, van der Boog PJM, de Fijter JW, Betjes MGH, Heidt S, Roelen DL, Claas FH, Otten HG, Hilbrands LB. Nephrol Dial Transplant; 2019 Aug 01; 34(8):1417-1422. PubMed ID: 30561730 [Abstract] [Full Text] [Related]
26. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine. Spagnoletti G, Citterio F, Favi E, Rossi E, Delreno F, De Santis I, Salerno MP, Gargiulo A, Castagneto M. Transplant Proc; 2009 May 01; 41(4):1175-7. PubMed ID: 19460509 [Abstract] [Full Text] [Related]
27. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. Treede H, Klepetko W, Reichenspurner H, Zuckermann A, Meiser B, Birsan T, Wisser W, Reichert B, Munich and Vienna Lung Transplant Group. J Heart Lung Transplant; 2001 May 01; 20(5):511-7. PubMed ID: 11343977 [Abstract] [Full Text] [Related]
29. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J. Liver Transpl; 2004 Jun 01; 10(6):728-33. PubMed ID: 15162466 [Abstract] [Full Text] [Related]
30. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O. Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912 [Abstract] [Full Text] [Related]
31. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A. Transplantation; 2006 Jul 15; 82(1):62-8. PubMed ID: 16861943 [Abstract] [Full Text] [Related]
35. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. Reggiani P, Arru M, Regazzi M, Gatti S, Molinaro MD, Caccamo L, Maggi U, Melada E, Paone G, Rossi G. Transplant Proc; 2005 May 15; 37(4):1697-9. PubMed ID: 15919435 [Abstract] [Full Text] [Related]
36. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Bruce DS, Sollinger HW, Humar A, Sutherland DE, Light JA, Kaufman DB, Alloway RR, Lo A, Stratta RJ. Transplantation; 2001 Nov 27; 72(10):1637-43. PubMed ID: 11726823 [Abstract] [Full Text] [Related]